NCT01529528

A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients

A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 117 (actual)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet therapy or combination of diet and exercise therapy.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Anagliptin	Anagliptin 100mg, tablet, BID
DRUG	Anagliptin	Anagliptin 100mg, tablet, BID
DRUG	Placebo of Anagliptin	Placebo of Anagliptin 100mg, tablet, BID

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-09-01
• Completion: 2012-11-01
• First posted: 2012-02-09
• Last updated: 2013-01-04

Locations

1 site across 1 country: South Korea